DGX 📈 Quest Diagnostics - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74834L1008

DGX: Diagnostic Tests, Laboratory Services, Medical Information

Quest Diagnostics Incorporated is a leading provider of diagnostic testing and services, operating in the United States and internationally. The company's core business involves developing and delivering a wide range of diagnostic information services, including routine, non-routine, and advanced clinical testing, as well as anatomic pathology testing.

These services are offered under various brands, including Quest Diagnostics, AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, catering to a diverse customer base that includes physicians, hospitals, patients, consumers, health plans, government agencies, employers, retailers, pharmaceutical companies, insurers, and accountable care organizations. The company's extensive network of laboratories, patient service centers, and mobile healthcare professionals enables it to provide convenient and accessible diagnostic services to its customers.

In addition to its diagnostic services, Quest Diagnostics also provides risk assessment services to the life insurance industry, helping insurers make informed decisions about policyholders. Furthermore, the company offers healthcare organizations and clinicians information technology solutions, empowering them to make data-driven decisions and improve patient care.

With a rich history dating back to 1967, Quest Diagnostics Incorporated is headquartered in Secaucus, New Jersey, and has established itself as a trusted partner in the healthcare industry. For more information, please visit their website at https://www.questdiagnostics.com.

Additional Sources for DGX Stock

DGX Stock Overview

Market Cap in USD 18,229m
Sector Healthcare
Industry Diagnostics & Research
GiC Industry Health Care Providers & Services
TER 0.00%
IPO / Inception 1996-12-17

DGX Stock Ratings

Growth 5y 60.2%
Fundamental 34.2%
Dividend 56.7%
Rel. Performance Sector 0.65
Analysts 3.83/5
Fair Price Momentum 166.17 USD
Fair Price DCF 237.12 USD

DGX Dividends

Dividend Yield 12m 1.83%
Yield on Cost 5y 3.08%
Annual Growth 5y 5.65%
Payout Consistency 98.36%

DGX Growth Ratios

Growth Correlation 3m 71.3%
Growth Correlation 12m 87.6%
Growth Correlation 5y 72.5%
CAGR 5y 10.99%
CAGR/Mean DD 5y 0.88
Sharpe Ratio 12m 0.89
Alpha -5.57
Beta 0.80
Volatility 18.64%
Current Volume 673.1k
Average Volume 20d 880.7k
What is the price of DGX stocks?
As of December 04, 2024, the stock is trading at USD 161.94 with a total of 673,140 shares traded.
Over the past week, the price has changed by -0.20%, over one month by +4.93%, over three months by +3.68% and over the past year by +20.32%.
Is Quest Diagnostics a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Quest Diagnostics is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 34.24 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DGX as of December 2024 is 166.17. This means that DGX is currently overvalued and has a potential downside of 2.61%.
Is DGX a buy, sell or hold?
Quest Diagnostics has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy DGX.
  • Strong Buy: 7
  • Buy: 1
  • Hold: 10
  • Sell: 0
  • Strong Sell: 0
What are the forecast for DGX stock price target?
According to ValueRays Forecast Model, DGX Quest Diagnostics will be worth about 181 in December 2025. The stock is currently trading at 161.94. This means that the stock has a potential upside of +11.74%.
Issuer Forecast Upside
Wallstreet Target Price 167.3 3.3%
Analysts Target Price 146.3 -9.7%
ValueRay Target Price 181 11.7%